期刊文献+

孕早期Down综合征(DS)的产前筛查

First-trimester prenatal screening for Down syndrome
暂未订购
导出
摘要 目的 :探讨孕早期Down综合征 (DS)的产前筛查。方法 :时间分辨荧光免疫法 (TRFIA)对孕 8~ 13周的 5 43 3例孕妇血清中 β hCG、PAPP A2两项血清标记物进行检测 ,比较分析 8例DS胎儿母血清与 184例对照病例血清中两种标记物水平。结果 :DS组母血中 β hCG、PAPP A平均值分别为 2 .3 1MoM和 0 .42MoM ,与对照组差别有显著性意义 (P <0 .0 5 ) ;β hCG、PAPP A两项指标联合筛查 ,DS的阳性检出率为 75 % ,假阳性率为8.3 5 %。结论 :孕早期 β hCG、PAPP A两联标记物筛查DS可以达到孕中期三联标记物筛查效果。 Objective: To investigate the performance of first-trimester prenatal screening for Down syndrome.Methods: Maternal serum were collected from 5433 pregnant women between 8 and 13 weeks gestation,prior to having a chorionic villus sampling procedure.Free β glycoprotein sub-units of human chorionic gonadotrophin (β-hCG)?pregnancy-associated plasma protein(PAPP-A) were measured using time resolued fluorescence immunoassay(TRFIA).The levels of two markers was analyzed between 8 pregnancies women with DS and 184 control pregnancies women.Results: The levels of markers differed between affected and unaffected pregnancies sufficiently.The median free β-hCG level in affected pregnancies was 2.31 times the median level for unaffected pregnancies,and the median PAPP-A level was 0.42 times the unaffected median.The combination of the two markers estimate a women's risk of having a fetus with Down syndrome.A screening programme that used a risk cutoff level of 1∶250 would detect 75% of affected pregnancies and a 8.35% false-positive rate.Conclusion: The performance of screening using maternal serum free β-hCG and PAPP-A at first-trimester was similar to the triple test at second trimester.
出处 《河南医学研究》 CAS 2003年第4期316-318,共3页 Henan Medical Research
基金 河南省医学科技创新人才工程项目 ( 2 0 0 186)
关键词 孕早期 DOWN综合征 时间分辨荧光免疫法 产前筛查 Β-HCG PAPP-A2 Down syndrome prenatal screening first-trimester
  • 相关文献

参考文献8

  • 1[1]Bryant LD,Green JM,Newison J.Prenatal screening for Down syndrome:Some psychosocial implications of a ‘screening for all' policy[J].Public Health,2001,115(5):256-358.
  • 2[2]Knight GJ,Palomaki GE,Neveux LM,et al.Clinical validation of new dimeric inhibin-A assay suitable for second trimester Down syndrome screening[J].J Med Screen,2001,8(1):2-7.
  • 3[3]Holding S.Current state of screening for Down syndrome[J].Ann Clin Biochem,2002,39(Pt1):1-11.
  • 4[4]Niemimaa M,Suonpaa M,Perheetupa A,et al.Evaluation of first trimester maternal serum and ultrasound screening for Down syndrome in Eastern and Northern Finland[J].Eur J Hum Genet,2001,9(6):101-108.
  • 5[5]Wald NJ,George L,Smith D,et al.Serum screening for Down syndrome between 8 and 14 weeks of pregnancy[J].Br J Obster Gynaecol,1996,103(5):407-412.
  • 6[6]Baviera G,Corrado F,Carbone C.Prostate-specific antigen in prenatal screening for Down syndrome[J].Eur J Obstet Gynecol Reprod Biol,2001,96(2):238.
  • 7[7]Knight GJ,Palomaki GE,Neveux LM,et al.Clinical validation of new dimeric inhibin-A assay suitable for second trimester Down syndrome screening[J].J Med Screen,2001,8(1):2-7.
  • 8[8]Cuckle HS,Vanlith JM.Appropriate biochemical parameters in first-trimester screening for Down syndrome[J].Prenat Diagn,1999,19(6):505-512

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部